DEPO-PROVERA WARNING: THE CONTRACEPTIVE LINKED TO BRAIN TUMOURS

I have been looking much more deeply into Depo-Provera, and the more I followed the evidence, the history and the commercial side of this contraceptive injection, the more questions I found myself asking. This is a product that has been used by millions of women, yet we are now dealing with research heavily linking its active ingredient, high-dose medroxyprogesterone acetate, with meningioma, a tumour arising from the membranes surrounding the brain and spinal cord. What caught my attention was not simply one study, but the combination of long-term exposure, clinical-trial follow-up, emerging safety evidence, substantial product sales and the pharmaceutical marketing structure surrounding the drug.

THE BRAIN TUMOUR EVIDENCE: In 2024, research published in the BMJ examined injectable medroxyprogesterone acetate and intracranial meningioma. The study reported an odds ratio of 5.55 for injectable medroxyprogesterone acetate, with the increased risk driven by prolonged use of at least one year. For prolonged use specifically, the odds ratio was 5.62. That finding immediately raised an important question for me: what happens when a medicine is used repeatedly for many years, particularly when the potential adverse effect being investigated take long periods of time to become apparent?

THIS IS NOW A FORMAL SAFETY ISSUE: The significance of this evidence increased when the UK Medicines and Healthcare products Regulatory Agency and Pfizer issued a healthcare professional communication in October 2024 concerning meningioma and high-dose medroxyprogesterone acetate. The communication identified a significant increased risk, particularly following prolonged use over several years, and the medicines safety information was updated. For me, that makes this much bigger than a debate happening on social media. The safety information surrounding the medicine has changed. Yet marketing and sales continue.

THEN I LOOKED AT THE TRIALS: I wanted to understand how long women were actually studied during the development of the evidence base. The US prescribing information describes more than 3,900 women participating in clinical trials, with treatment lasting from one month to seven years. However, the median study duration was ONLY 13 months. Approximately 58% of participants remained after 13 months and 34% remained after 24 months, with substantially fewer participants remaining for the longest periods. This distinction matters to me because "studied for up to seven years" and "median study duration of 13 months" communicate two very different things when we are discussing safety issues.

THE LONG-TERM QUESTION: The BMJ research found that the increased risk was associated with prolonged use, which makes cumulative exposure particularly relevant. A woman receiving an injection for several months has a very different exposure history from someone receiving repeated injections for ywo, three, five, ten or twenty years. I therefore think it is reasonable to ask how effectively uncommon, delayed adverse effects can be identified when most clinical-trial participants are not followed for many years, and how much additional information becomes available only after a medicine is used by millions of people in the real world.

I FOLLOWED THE MONEY: Once I had examined the evidence, I started looking at the commercial side because I wanted to understand the scale of the financial interests surrounding this product. Historical US market data reported approximately $211 million in annual Depo-Provera sales in 2017. During the late 1990s, Pharmacia & Upjohn also expanded its US prescription pharmaceutical sales force by more than 600 representatives and managers, with Depo-Provera among the products being promoted. Pharmaceutical sales positions have operated with performance-related compensation and sales incentives, including quarterly sales incentive bonuses and historical field-force incentive programmes connected to product performance and sales. I specifically wanted to know whether there was a documented commission paid to representatives for every Depo-Provera sale, but I could not find a reliable public figure establishing a specific per-sale commission. What is documented is a pharmaceutical sales structure designed to promote products and increase utilisation, with performance incentives forming part of that commercial environment. The wider contraceptive advertising market was also enormous. Research found that pharmaceutical companies spent $1.57 billion on direct-to-consumer advertising of prescription contraceptives in the United States between 2005 and 2014, with annual spending reaching approximately $260 million in 2008. That figure covers prescription contraceptives collectively, not Depo-Provera specifically, but it demonstrates the scale of the commercial market surrounding hormonal contraception. Did the money come before the health is a good question.

THIS IS WHERE I STARTED ASKING HARDER QUESTIONS: When I put the evidence and commercial history together, I see a product that generated approximately $211 million in US sales in 2017, a pharmaceutical sales structure involving representatives and performance incentives, a huge contraceptive advertising industry and emerging evidence concerning prolonged exposure and meningioma. That does not answer every question, but it makes the questions impossible for me to ignore. How clearly were women informed about the developing evidence? How quickly did information reach patients? And how many women understood the potential significance of prolonged exposure?

HOW MANY WOMEN KNEW?: This is the question that stays with me. How many women receiving Depo-Provera for years knew about the emerging meningioma evidence? How many knew that prolonged exposure was relevant? How many were given an opportunity to discuss alternatives? And how many are only discovering this information now because they happened to read a newspaper report or see someone discussing the research online? Hpw many fpund out because they were diognosed with tumors? How many will continue to die whilst high proffits continue.

THE WORD "BENIGN" DOES NOT TELL THE WHOLE STORY: Meningiomas are generally classified as non-cancerous, but their location can make them medically serious. Depending on their size and position, they can cause headaches, seizures, visual problems, hearing changes, weakness, numbness, balance difficulties and other neurological symptoms and death. Some require surgery or other treatment. Calling a tumour "benign" does not mean that its consequences are minor or they don't cause death!

THE WOMAN AT THE CENTRE OF THIS STORY: When I strip away the statistics, pharmaceutical companies, sales figures and regulatory documents, I keep coming back to the woman receiving the injection. She may have been receiving it for years. She may trust her doctor. She may assume that if important new evidence emerged, someone would tell her. She may never have seen the scientific paper or regulatory communication. That is why I believe informed consent is so important. A woman cannot weigh information she has never been given.

SAFE OPTION. I used the calendar rhythm method and only stopped using it when I wanted to conceive. There are also fertility awareness-based methods that use cycle tracking, along with ovulation tests that can help identify the fertile window. When practiced correctly and consistently, fertility awareness-based methods are an effective form of contraception, although their effectiveness depends on accurately identifying the fertile days and avoiding unprotected sex during that window. The only real downside to ovulation tests is that you may have to urinate on your fingers, although that can easily be avoided too. Doctors don't seem to mention calender rythem method based methods as a contraceptive option anymore, is this simply because explanations take longer than writing a prescription? Or is because an explanation has no Monetary value?

MY PERSONAL VIEW: If I were considering Depo-Provera today, I would want to know about the meningioma evidence before receiving another injection. I would want to know how long I had already been exposed, what the current research showed, how duration affected the findings and what alternatives were available. I would want the information presented clearly enough that I could make my own decision rather than simply being expected to trust that everything had already been considered for me.

I BELIEVE WOMEN DESERVE THE WHOLE STORY: They deserve to know the benefits, the risks, the emerging evidence, the duration-related concerns and the alternatives. They deserve to understand the numbers rather than simply being told that something is safe or unsafe. They deserve access to the information before making the decision, not years afterwards when they discover a safety warning for themselves.

I FOLLOWED THE MONEY. THEN I FOLLOWED THE EVIDENCE. NOW I AM ASKING WOMEN TO FOLLOW THE QUESTIONS. Because ultimately, the woman receiving the injection is the one who has to live with the consequences of her decision, and I believe she deserves all the information necessary to make it.